Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial

被引:17
|
作者
Onichimowski, Dariusz [1 ]
Bedzkowska, Anita [2 ]
Ziolkowski, Hubert [3 ]
Jaroszewski, Jerzy [3 ]
Borys, Michal [4 ]
Czuczwar, Miroslaw [4 ]
Wiczling, Pawel [2 ]
机构
[1] Univ Warmia & Mazury, Dept Anesthesiol & Intens Care, Fac Med, Ul Zolnierska 18, PL-10900 Olsztyn, Poland
[2] Med Univ Gdansk, Dept Biopharmaceut & Pharmacodynam, Gdansk, Poland
[3] Univ Warmia & Mazury, Dept Pharmacol & Toxicol, Fac Vet Med, Olsztyn, Poland
[4] Med Univ Lublin, Dept Anaesthesiol & Intens Therapy 2, Lublin, Poland
关键词
Sepsis; Meropenem; Pharmacokinetic modelling; Critically ill; Renal replacement therapy; SEPTIC SHOCK; PHARMACODYNAMICS;
D O I
10.1007/s43440-020-00104-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background The primary objective of this study was to develop a population pharmacokinetic model of meropenem, based on the population of critically ill adult patients undergoing CRRT. The secondary one was to examine the relationship between patient characteristics (covariates) and individual PK parameters. Finally, we aimed to perform Monte Carlo simulations to assess the probability of target attainment (PTA) of %T > MIC considering the uncertainty of PK parameters. Materials and methods The study population included 19 adult critically ill patients on CRRT, receiving 1 g of meropenem in 1-h infusions every 8 h. Blood samples were collected prior to (time zero) and 15, 30, 45, 60, 75, 90, 120, 180, 240 and 480 min after the start of meropenem administration. Population nonlinear mixed-effects modeling was conducted using NONMEM software, Fortran, and Wings for NONMEM. Results A two-compartment model was used to describe the available data. Typical values of the central and peripheral volume of distribution, and the CRRT and inter-compartmental clearance for a theoretical patient with 24.6 g/l albumin concertation wereV(1) = 27.9 l,V-2 = 33.7 l,Cl-CRRT = 15.1 l/h, andQ = 21.1 l/h. A significant covariate relationship betweenV(1)and albumin concentration was observed in the data that was described by a power relationship with - 2.87 exponent. Subsequently performed Monte Carlo simulations of the model allowed us to assess the impact of albumin concentration on PTA. The 40%T > 2 mg/l target was reached in more than 90% of subjects after 1-h infusion of 1000 mg q8h and steady-state conditions. The more stringent 100%T > 2 mg/l target requires higher doses and/or longer infusion durations that depend on the albumin concentration. Conclusions The population PK model was successfully developed to describe the time course of meropenem concentrations. The hypoalbuminemia was found to be associated with higher PTA in the CRRT patients after multiple short-term infusions.
引用
收藏
页码:719 / 729
页数:11
相关论文
共 50 条
  • [1] Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial
    Dariusz Onichimowski
    Anita Będźkowska
    Hubert Ziółkowski
    Jerzy Jaroszewski
    Michał Borys
    Mirosław Czuczwar
    Paweł Wiczling
    Pharmacological Reports, 2020, 72 : 719 - 729
  • [2] Population Pharmacokinetics of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
    Arantxazu Isla
    Alicia Rodríguez-Gascón
    Iñaki F. Trocóniz
    Lorea Bueno
    María Ángeles Solinís
    Javier Maynar
    José Ángel Sánchez-Izquierdo
    José Luis Pedraz
    Clinical Pharmacokinetics, 2008, 47 : 173 - 180
  • [3] Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy
    Isla, Arantxazu
    Rodriguez-Gascon, Alicia
    Troconiz, Inaki F.
    Bueno, Lorea
    Angeles Solinis, Maria
    Maynar, Javier
    Angel Sanchez-Izquierdo, Jose
    Luis Pedraz, Jose
    CLINICAL PHARMACOKINETICS, 2008, 47 (03) : 173 - 180
  • [4] Pharmacokinetics of meropenem during continuous renal replacement therapy in critically ill patients
    J Solé Violan
    J Ferrer Agüero
    B Sádaba
    S Sancho
    R Zaragoza
    P Luque
    M Nieto
    M López
    F García
    C Hernández
    J Azanza
    Critical Care, 18 (Suppl 1):
  • [5] Integration of Continuous Renal Replacement Therapy in a Meropenem Population Pharmacokinetics Model in Critically Ill Children
    Beranger, Agathe
    Bouazza, Naim
    Oualha, Mehdi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (04)
  • [6] Meropenem Population Pharmacokinetics in Critically Ill Patients with Septic Shock and Continuous Renal Replacement Therapy: Influence of Residual Diuresis on Dose Requirements
    Ulldemolins, Marta
    Soy, Dolors
    Llaurado-Serra, Mireia
    Vaquer, Sergi
    Castro, Pedro
    Rodriguez, Alejandro H.
    Pontes, Caridad
    Calvo, Gonzalo
    Torres, Antoni
    Martin-Loeches, Ignacio
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (09) : 5520 - 5528
  • [7] Meropenem population pharmacokinetics and dosing regimen optimization in critically ill children receiving continuous renal replacement therapy
    Thy, M.
    Urien, S.
    Bouazza, N.
    Foissac, F.
    Bille, E.
    Rapp, M.
    Beranger, A.
    Lui, G.
    Lesage, F.
    Renolleau, S.
    Treluyer, J. M.
    Oualha, M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 92 - 93
  • [8] Meropenem Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy
    Michael Thy
    Saik Urien
    Naim Bouazza
    Frantz Foissac
    Inès Gana
    Emmanuelle Bille
    Agathe Béranger
    Julie Toubiana
    Romain Berthaud
    Fabrice Lesage
    Sylvain Renolleau
    Jean-Marc Tréluyer
    Sihem Benaboud
    Mehdi Oualha
    Clinical Pharmacokinetics, 2022, 61 : 1609 - 1621
  • [9] Population Pharmacokinetics of Tigecycline for Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
    Song, Shuping
    Liu, Jieqiong
    Su, Wei
    Yu, Haitao
    Feng, Binbin
    Wu, Yinshan
    Guo, Feng
    Yu, Zhenwei
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 4459 - 4469
  • [10] Clearance of meropenem during continuous renal replacement therapy in critically ill patients
    F Thalhammer
    P Schenk
    H Burgmann
    UM Hollenstein
    K Ratheiser
    S Breyer
    Critical Care, 3 (Suppl 1):